Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Modern Valves Reduce the Need for a Pacemaker

Courtesy of Dr. Carlos Fava.

Transcatheter aortic valve replacement (TAVR) has already demonstrated benefit for different risk groups, but one of the remaining challenges is the reduction of the need for a pacemaker, which is still high for self-expanding valves compared with expandable balloons.

The study enrolled 203 patients with severe aortic stenosis who underwent TAVR with a CENTERA self-expanding valve (Edwards Lifesciences, Irvine, California).

 

The mean age was 82 years, two thirds of these patients were women, the Society of Thoracic Surgeons score was 6.1, most patients were New York Heart Association functional class III or IV, 33.5% suffered from renal impairment, 7.9% had a prior pacemaker implantation, and their mean ejection fraction was 55%.

 

At 30 days, mortality was 1%, stroke was 4%, disabling stroke was 2.5%, acute myocardial infarction was 1.5%, permanent pacemaker implantation was 4.9%, and major bleeding was 14.4%.


Read also: Bundle Branch Block and Need for Permanent Pacemaker, a Major Challenge after TAVR.


After a 1-year follow-up, overall mortality was 9.1%, cardiovascular mortality was 4.6%, disabling stroke was 4.1%, new pacemaker implantation was 6.5%, and hospital readmission due to cardiac reasons was 6.8%. The mean aortic valve gradient was 8.1 ± 4.7 mmHg, the mean effective orifice area was 1.7 ± 0.42 cm2, and there was no severe or moderate aortic regurgitation.

 

Conclusion

The CENTERA-EU trial demonstrated mid-term safety and effectiveness of the CENTERA valve. In addition to low mortality, it maintained its hemodynamic performance and low need for pacemaker after implantation in high-risk patients with severe aortic stenosis.

 

Courtesy of Dr. Carlos Fava.

 

Original title: 1-Year Outcomes of the CENTERA-EU Trial Assessing a Novel Self-Expanding Transcatheter Heart Valve.

Reference: Didier Tchétché et al. J Am Coll Cardiol Intv 2019;12:673-80


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Su opinión nos interesa. Puede dejar su comentario, reflexión, pregunta o lo que desee aquí abajo. Será más que bienvenido.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...